Table 2.
Estrone, Estradiol, and SHBG Concentrations (Geometric Means, 95% Confidence Intervals) at Baseline and 6 Month Follow-up
| Aspirin (N=76) | Placebo (N=68) |
P- Value* |
|||||
|---|---|---|---|---|---|---|---|
| Baseline (95% CI) |
Follow-up (95% CI) |
ΔA (%) | Baseline (95% CI) |
Follow-up (95% CI) |
ΔP (%) | ||
| Estrone (pg/mL) | 31.1 (29.0, 33.3) |
31.5 (29.4, 33.9) |
0.4 (1.3) | 33.4 (30.8, 36.2) |
33.3 (30.8, 36.1) |
−0.1 (−0.3) | 0.75 |
| Estradiol (pg/mL) | 7.25 (6.49, 8.09) |
7.42 (6.72, 8.20) |
0.17 (2.3) | 7.58 (6.84, 8.40) |
7.72 (6.92, 8.62) |
0.14 (1.8) | 0.94 |
| Free estradiol (pg/mL) | 0.177 (0.156, 0.200) |
0.180 (0.161, 0.202) |
0.003 (1.7) | 0.180 (0.159, 0.203) |
0.182 (0.160, 0.207) |
0.002 (1.1) |
0.96 |
| Bioavailable estradiol (pg/mL) |
4.53 (4.01, 5.11) |
4.58 (4.08, 5.13) |
0.05 (1.1) | 4.56 (404, 5.15) |
4.62 (4.08, 5.24) |
−0.06 (− 1.3) |
0.97 |
| SHBG (nmol/L) | 45.9 (41.5, 50.7) |
47.3 (42.7, 52.4) |
1.4 (3.1) | 51.1 (46.3, 56.4) |
51.7 (46.9, 57.0) |
0.6 (1.2) | 0.46 |
ΔP: change in control (placebo) group at 6 month from baseline; ΔA: change in Aspirin group at 6 month from baseline.
*
P value: GEE model, comparing the change at 6 month follow-up from baseline between Placebo and Aspirin group